TRAIL, Soluble, Recombinant, Human (Apo-2L, TNFSF10, CD253)

izTRAIL is a newly available, highly active recombinant form of soluble human TRAIL. Due to a trimerizing N-terminal isoleucine zipper (iz) motif the intrinsic trimerization of TRAIL, required for apoptosis-inducing activity of TRAIL, is enhanced when compared to non-tagged soluble human TRAIL (shTRAIL). Therefore, izTRAIL is a potent inducer of apoptosis in many human cancer cells, but not normal human hepatocytes. In addition, the half-life of izTRAIL is about eight-fold higher than the half-life of shTRAIL. These properties render izTRAIL highly suitable for both, in vitro and in vivo use, particularly for studies in which investigators plan to transfer their in vitro results into an in vivo system with human cancer cells in xenotransplant settings examining susceptibility to TRAIL-induced apoptosis.\n\nBiological Activity:\nInduces apoptosis in vitro in different human cancer cell lines with an EC50 of 5-200ng/ml, depending on the individual cell line used. Recombinant izTRAIL does not kill 4-day cultures of primary human hepatocytes (PHH) at concentrations of at least up to 1ug/ml (Ganten 2006). Good bioavailability in vivo, shows no toxic effects in mice at doses of at least up to 500ug per day (Wissink 2006).\n\nSequence:\nThe extracellular domain of human TRAIL (aa 95-281) is fused at the N-terminus to an isoleucine zipper motif.\n\nMolecular Weight:\n~82kD as stable trimers (determined by size exclusion chromatography) ~28kD as monomer (determined by SDS-PAGE)\n\nStorage and Stability:\nShort-term Storage: +4 degrees C\nLong-term Storage: -20 degrees C\nStable for at least 6 months after receipt when stored at -20 degrees C.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

045368

Size

10ug

Form

Supplied as a lyophilized powder from a 0.2um filtered solution in 20mM TRIS-Cl, 0.5M arginine-HCl, 100mM NaCl, 0.02% Tween 20.

Purity

>95% (SDS-PAGE)

References

Product Reference: Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs: T.M. Ganten, et al.; Clin. Cancer Res. 12, 2640 (2006)\n?TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy: E.H. Wissink, et al.; Radiother. Oncol. 80, 214 (2006)\n?Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis: R. Koschny, et al.; Clin. Cancer Res. 13, 3403 (2007)\n?TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window: R. Koschny, et al.; Hepatology 45, 649 (2007)

Additional Info

Binds to human TRAIL receptors 1-4 (TRAIL-R1 to TRAIL-R4); izTRAIL does not interact with the apoptosis-inducing mouse TRAIL receptor (TRAIL-R).

Alternative Names

Apo-2L, TNFSF10, CD253